PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 6 months ago Informations privilégiées / Autres communiqués Rapport du conseil d'administration de VALERIO THERAPEUTICS pour l'AG mixte des actionnaires du 9 avril 2025 concernant révocations, cooptations, division du nominal des actions et modifications statutaires Cooptation Revocation Valerio Therapeutics AG Mixte Division Du Nominal
PRESS RELEASE published on 03/19/2025 at 12:30, 1 year 6 months ago Inside Information / Other news releases Valerio Therapeutics Board of Directors convenes a General Meeting with resolutions on director dismissals, co-optation, share division, bylaws amendment, and formalities powers Board Of Directors General Meeting Resolutions Valerio Therapeutics Share Division
BRIEF published on 02/04/2025 at 10:40, 1 year 8 months ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
BRIEF published on 02/04/2025 at 10:40, 1 year 8 months ago Valerio Therapeutics opte pour un recentrage stratégique Innovation Médicale Stratégie Financière Essais Cliniques Oncologie Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 8 months ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 8 months ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce un recentrage stratégique pour se concentrer sur le développement de médicaments early-stage et assurer une croissance durable. La société cherche un accord de financement à long terme Développement Financement Restructuration Médicaments Valerio Therapeutics
BRIEF published on 10/01/2024 at 00:56, 2 years ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:56, 2 years ago Valerio Therapeutics publie ses résultats financiers du premier semestre 2024 Résultats Financiers R&D Essai Clinique Valerio Therapeutics Anticorps À Domaine Unique
PRESS RELEASE published on 10/01/2024 at 00:51, 2 years ago Inside Information: News release on accounts, results Valerio Therapeutics annonce ses résultats financiers du Premier Semestre 2024 et fait le point sur ses activités, y compris l'acquisition d'Emglev Therapeutics et le développement de la plateforme PlatONTM Résultats Financiers Biotechnologie Valerio Therapeutics Emglev Therapeutics Plateforme PlatONTM
BRIEF published on 10/01/2024 at 00:45, 2 years ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
Published on 10/15/2026 at 19:25, 13 minutes ago Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption
Published on 10/15/2026 at 16:10, 3 hours 28 minutes ago North Shore Announces Extension to Falcon Property Option Agreement and Resource Stock Digest Engagement
Published on 10/15/2026 at 15:15, 4 hours 23 minutes ago Gold Terra to Host Community Town Hall Meeting in Yellowknife on October 21, 2026
Published on 10/15/2026 at 14:31, 5 hours 7 minutes ago First Breach to Present at the 20th Annual LD Micro Main Event
Published on 10/15/2026 at 14:05, 5 hours 33 minutes ago Innodata to Report Third Quarter 2026 Results
Published on 10/15/2026 at 18:03, 1 hour 35 minutes ago AIXTRON Q3 2026: Order intake and operating profitability significantly exceed market expectations
Published on 10/15/2026 at 18:00, 1 hour 38 minutes ago BOA Concept Group étoffe son offre et intègre les AMR KUKA
Published on 10/15/2026 at 18:00, 1 hour 38 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/15/2026 at 18:00, 1 hour 38 minutes ago Supervisory Board appoints Dr. Marc-Alexander Mahl to the Fresenius Management Board and extends Sara Hennicken’s contract
Published on 10/15/2026 at 18:50, 48 minutes ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 18:50, 48 minutes ago Trafic du mois de septembre et des 9 premiers mois de l'année 2026 - Révision des hypothèses de trafic pour l'année 2026
Published on 10/15/2026 at 18:16, 1 hour 22 minutes ago Déclaration des droits de vote au 30 septembre 2026
Published on 10/15/2026 at 18:14, 1 hour 24 minutes ago Déclaration des droits de vote au 31 août 2026
